Efficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis
October 2019 | Volume 18 | Issue 10 | Original Article | 1038 | Copyright © October 2019
Zoe Diana Draelos MD,ª Michael Traub ND FABNO,B Michael H. Gold MD,c Lawrence J. Green MD,d Mark Amster MD,e Deganit Barak-Shinar PhD,f Leon H. Kircik MDg
ªDermatology Consulting Services, PLLC, High Point, NC
BHawaii Integrative Oncology Ho’o Lokahi, Kailua Kona, HI
cTennessee Clinical Research Center, Nashville, TN
dGeorge Washington University School of Medicine, Washington, DC
EMetro Boston Clinical Partners, LLC, Boston, MA
fKamedis Ltd. Tel-Aviv, Israel
gIcahn School of Medicine at Mount Sinai, NY;
Indiana Medical Center, Indianapolis, IN; Physicians Skin Care, PLLC,; DermResearch, PLLC, Louisville, KY
Design: The study was designed as an interventional, multi-center, double-blind, randomized, controlled study.
Setting: Children subjects were a sub-population of the 108 combined population of adults and children evenly randomly divided into three treatment groups: test product, vehicle, and comparator. The vehicle used was the identical test product without the botanical combination while the comparator was a leading OTC brand in the US market. All three groups used the same Kamedis body wash followed by one of the three randomized treatment creams for the affected areas.
Participants: Thirty-nine (39) children subjects with uncomplicated, stable, mild to moderate atopic dermatitis were recruited and qualified for the study, 24 female and 15 male, ages varying between 3 and 18.
Measurements: Investigators assessed the severity of each subject using the Investigator Global Assessment (IGA), affected Body Surface Area (BSA) extent evaluated parameters at each of the visit days 0, 7, 14, and 28. Subjective symptoms of pruritus and insomnia were evaluated by the patient or their legal guardian. The SCORAD and EASI indexes were calculated based on the collected parameters.
Results: The test product demonstrated an improvement in all evaluated and calculated clinical parameters over the vehicle at the end of the treatment duration, proving the validation that the test product is much more effective and beneficial than the vehicle. The test product reached 40% of 'clear' IGA subjects out of the enrolled subjects and 60% out of the 'clear' and 'almost clear' IGA subjects comparing to 8% and 38%, respectively, with the vehicle, presenting a clear advantage over the vehicle. The BSA improvement comparison analysis of the test product over the vehicle yielded P value of less than 0.05, which is statistically significant. The SCORAD and EASI indexes also showed an advantage of the test product versus the vehicle at week 4.
Conclusion: The study results validate that the botanical combination is the key factor for the efficacy and improvement of the AD symptoms within this population of children.
J Drugs Dermatol. 2019;18(10):1038-1045.